|
Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS) DCF Valuation
CN | Healthcare | Medical - Devices | SHH
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS) Bundle
Enhance your investment strategies with the (688298SS) DCF Calculator! Explore real financial data for Zhejiang Orient Gene Biotech Co., Ltd., adjust growth projections and expenses, and instantly observe how these modifications affect the intrinsic value of (688298SS).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 367.4 | 3,265.4 | 10,169.2 | 8,767.9 | 820.2 | 1,016.1 | 1,258.9 | 1,559.7 | 1,932.4 | 2,394.1 |
| Revenue Growth, % | 0 | 788.83 | 211.43 | -13.78 | -90.65 | 23.89 | 23.89 | 23.89 | 23.89 | 23.89 |
| EBITDA | 101.5 | 1,981.8 | 5,811.9 | 2,564.3 | -200.0 | 305.5 | 378.5 | 469.0 | 581.0 | 719.9 |
| EBITDA, % | 27.63 | 60.69 | 57.15 | 29.25 | -24.38 | 30.07 | 30.07 | 30.07 | 30.07 | 30.07 |
| Depreciation | 7.4 | 9.1 | 39.6 | 95.1 | 165.5 | 48.6 | 60.3 | 74.7 | 92.5 | 114.6 |
| Depreciation, % | 2.01 | 0.27895 | 0.38915 | 1.08 | 20.18 | 4.79 | 4.79 | 4.79 | 4.79 | 4.79 |
| EBIT | 94.2 | 1,972.7 | 5,772.4 | 2,469.2 | -365.5 | 256.9 | 318.3 | 394.3 | 488.5 | 605.3 |
| EBIT, % | 25.63 | 60.41 | 56.76 | 28.16 | -44.56 | 25.28 | 25.28 | 25.28 | 25.28 | 25.28 |
| Total Cash | 85.4 | 2,237.6 | 6,266.2 | 7,757.7 | 5,217.0 | 694.8 | 860.8 | 1,066.5 | 1,321.3 | 1,637.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 83.0 | 625.8 | 1,184.4 | 309.4 | 207.7 | 167.2 | 207.1 | 256.6 | 317.9 | 393.9 |
| Account Receivables, % | 22.6 | 19.17 | 11.65 | 3.53 | 25.33 | 16.45 | 16.45 | 16.45 | 16.45 | 16.45 |
| Inventories | 78.0 | 381.6 | 470.6 | 431.9 | 346.8 | 172.2 | 213.4 | 264.3 | 327.5 | 405.8 |
| Inventories, % | 21.22 | 11.69 | 4.63 | 4.93 | 42.28 | 16.95 | 16.95 | 16.95 | 16.95 | 16.95 |
| Accounts Payable | 49.2 | 372.0 | 1,173.7 | 1,580.1 | 600.5 | 259.2 | 321.1 | 397.9 | 492.9 | 610.7 |
| Accounts Payable, % | 13.38 | 11.39 | 11.54 | 18.02 | 73.22 | 25.51 | 25.51 | 25.51 | 25.51 | 25.51 |
| Capital Expenditure | -11.9 | -126.9 | -507.9 | -1,051.9 | -996.0 | -252.2 | -312.5 | -387.2 | -479.7 | -594.3 |
| Capital Expenditure, % | -3.24 | -3.89 | -4.99 | -12 | -121.45 | -24.82 | -24.82 | -24.82 | -24.82 | -24.82 |
| Tax Rate, % | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 |
| EBITAT | 84.7 | 1,676.0 | 4,922.2 | 2,066.4 | -359.5 | 227.2 | 281.5 | 348.7 | 432.1 | 535.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -31.7 | 1,034.6 | 4,608.0 | 2,429.7 | -1,982.8 | -102.6 | 10.1 | 12.5 | 15.5 | 19.2 |
| WACC, % | 11.61 | 11.59 | 11.59 | 11.58 | 11.64 | 11.6 | 11.6 | 11.6 | 11.6 | 11.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -53.8 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 20 | |||||||||
| Terminal Value | 245 | |||||||||
| Present Terminal Value | 141 | |||||||||
| Enterprise Value | 88 | |||||||||
| Net Debt | -3,468 | |||||||||
| Equity Value | 3,555 | |||||||||
| Diluted Shares Outstanding, MM | 202 | |||||||||
| Equity Value Per Share | 17.62 |
Benefits You Will Receive
- Customizable Excel Template: A tailored Excel-based DCF Calculator featuring pre-filled financial data for Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- Accurate Data: A compilation of historical data along with forward-looking estimates (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA margin, and WACC to suit your analysis.
- Instant Calculations: Quickly observe how your inputs affect the valuation of Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- Professional Tool: Designed specifically for investors, CFOs, consultants, and financial analysts.
- User-Centric Design: Organized for clarity and ease of navigation, complemented by detailed step-by-step instructions.
Key Features
- 🔍 Real-Life ZOG Financials: Pre-filled historical and projected data for Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- ✏️ Fully Customizable Inputs: Modify essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas compute the intrinsic value of ZOG using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize ZOG's valuation immediately after input adjustments.
- Scenario Analysis: Analyze and compare the results of different financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template featuring Zhejiang Orient Gene Biotech Co., Ltd. (688298SS) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view the updated results, including the intrinsic value of Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- Step 5: Make well-informed investment choices or create reports based on the generated outputs.
Why Opt for Zhejiang Orient Gene Biotech Co., Ltd. (688298SS)?
- Precision: Leverage reliable financial data for accurate insights.
- Versatility: Tailored to allow users to experiment and adjust parameters effortlessly.
- Efficiency: Eliminate the need to construct a financial model from the ground up.
- Expert-Level: Crafted with the expertise and usability expected at the CFO level.
- Intuitive: Designed for ease of use, suitable for individuals without extensive financial modeling skills.
Who Can Benefit from This Product?
- Biotech Students: Master analytical methods and apply them to real-world data.
- Researchers: Integrate advanced models into your studies or academic projects.
- Investors: Validate your investment strategies and assess valuation metrics for Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- Market Analysts: Enhance your analysis with a ready-to-use, customizable valuation model.
- Entrepreneurs: Understand the evaluation process of public biotech companies like Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
Contents of the Template
- Pre-Filled DCF Model: Financial data for Zhejiang Orient Gene Biotech Co., Ltd. (688298SS) preloaded for immediate application.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess profitability, leverage, and efficiency of Zhejiang Orient Gene Biotech Co., Ltd. (688298SS).
- Editable Inputs: Modify assumptions such as growth rates, margins, and CAPEX to align with your scenarios.
- Financial Statements: Access annual and quarterly reports for in-depth analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.